Skip to main content
Addgene

BAP1-C91A
(Plasmid #108440)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 108440 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pCI-puro
  • Backbone manufacturer
    Dr. J. Mirkovitch, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland
  • Backbone size w/o insert (bp) 5224
  • Vector type
    Mammalian Expression
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    BAP1
  • Alt name
    UCHL2
  • Alt name
    hucep-6
  • Alt name
    HUCEP-13
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    2190
  • Mutation
    C91A: c.271T>G, c.272G>C
  • GenBank ID
    NM_004656.3
  • Entrez Gene
    BAP1 (a.k.a. HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2, hucep-6)
  • Promoter CMV

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site NheI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer T7
    • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    BAP1-C91A was a gift from Emanuela Felley-Bosco & Rolf Stahel (Addgene plasmid # 108440 ; http://n2t.net/addgene:108440 ; RRID:Addgene_108440)

  • For your References section:

    Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition. Okonska A, Buhler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E. Mol Cancer Ther. 2019 Oct 16. pii: 1535-7163.MCT-19-0356. doi: 10.1158/1535-7163.MCT-19-0356. 10.1158/1535-7163.MCT-19-0356 PubMed 31619462
Related items:
Commonly requested with: